Site map
An overview of the available content on this site. Keep the pointer still over an item for a few seconds to get its description.
- Plain language summary published in Clinical Kidney Journal
- Empagliflozin recommended for the treatment of adults with chronic kidney disease
- Empagliflozin reduces the risk of kidney disease progression or cardiovascular death in people with chronic kidney disease
- SGLT-2 inhibitors reduce the risk of cardiovascular death or hospitalisation for heart failure in adults with chronic kidney disease
- EMPA-KIDNEY trial stops early due to evidence of efficacy
- EMPA-KIDNEY design paper summary for patients with kidney disease
- Open access EMPA-KIDNEY design and baseline paper published
- EMPA-KIDNEY rationale paper published
- People living with chronic kidney disease may benefit more from longer-term use of -flozins
- What is the treatment being tested?
- How have we identified potential participants?
- What will participation involve?
- Do people invited to take part have to join the study?
- Who decides what treatment people get given?
- What happens at appointments?
- What happens at appointments (table summary)?
- What if a participant wants to leave the study?
- What happens to blood and urine samples?
- How might stored samples contribute to future research?
- What are the benefits of taking part in the study?
- Are there any risks to taking part in the study?
- Are there any other possible disadvantages of taking part?
- What will happen at the end of the main part of the study?
- What if there is a problem during or after the study?